A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)

2018121 citationsJournal Article

Authors

Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline <i>BRCA</i> mutation.

Good health and well-being

Published in: Clinical Cancer Research

Volume 25, Issue 9, pp. 2717-2724

Field-Weighted Citation Impact: 5.95